Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24 USD | +0.36% | -0.06% | -13.34% |
May. 23 | Cantor Fitzgerald Adjusts Alkermes Price Target to $48 From $43, Maintains Overweight Rating | MT |
May. 02 | UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.34% | 4.05B | |
+48.67% | 57.87B | |
+41.65% | 40.25B | |
-6.96% | 39.94B | |
-5.96% | 28.54B | |
+12.69% | 26.4B | |
-20.08% | 19.33B | |
+30.79% | 12.4B | |
-0.22% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- ALKS Stock
- News Alkermes plc
- Transcript : Alkermes plc Presents at Bank of America 2022 Virtual Biotech SMID Cap Conference, Dec-07-2022 08